JP2001270815A - Composition for external use - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a composition for external use for preventing a skin lesion, free from a problem of a smell, capable of introducing metallothionine to be a key component in a skin cell for preventing an organism from a skin lesion by solar ultraviolet radiation, or the like, and promoting the production of metallothionine by finding a means for percutaneous absorption of a higher fatty acid zinc salt. SOLUTION: This composition for external use for preventing skin lesion comprises a polar oil derivative having >=0.1 I.O.B. value exhibiting a degree of polarity of an oil and the higher fatty acid zinc salt to solve the problem.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

TECHNICAL FIELD The present invention relates to an external composition which can be used as an external preparation for skin and the like.

[0002]

2. Description of the Related Art In modern society, the skin is exposed to various injuries that damage skin cells. A typical example of these injuries is exposure to ultraviolet light from the sun.

[0003] Natural sunlight is composed of ultraviolet rays, visible rays, infrared rays and the like, and it is known that ultraviolet rays among them mainly cause skin damage. In other words, sunburn is an acute inflammatory reaction caused by excessive ultraviolet light exposure, in which epidermal cells are damaged and form sunburn cells (sunburn cells), which are necrotic epidermal cells, and may leave pigmentation behind. Many. Furthermore, it is said that as a result of a chronic reaction caused by ultraviolet rays, skin aging is accelerated and a precancerous condition may be reached.

At present, in order to protect the living body from such ultraviolet rays, a composition for external use (sunscreen) for protecting against ultraviolet rays, which contains an ultraviolet absorber or an ultraviolet scattering agent, is widely used.
The necessity of protecting the living body from ultraviolet rays from the sun is becoming more and more important together with recent phenomena such as destruction of the ozone layer.

[0005] Under such circumstances, it has been desired to provide better means for protecting the living body from ultraviolet rays from the sun. In particular, the function of the conventional sunscreen is to block or absorb ultraviolet rays from the sun on the skin, thereby preventing the ultraviolet rays from reaching skin cells.

However, there has not yet been provided an external preparation having a function of improving the protective action of the living body itself against ultraviolet rays from the sun and sufficiently preventing the occurrence of the sunburn cell described above.

[0007]

As one of the main means for providing a new means for protecting a living body from skin injuries caused by ultraviolet rays from the sun, etc. It is possible to find a key substance in skin defense, which has a function of removing the skin cell itself, and which the living body itself has, and to provide an external preparation or the like which can promote the production of the key substance in skin cells. No.

That is, the living body has a mechanism for protecting the body against harmful ultraviolet rays. For example, melanin contained in darkened skin is a useful ultraviolet protective substance because it has a free radical scavenging effect by itself. In addition, urocanic acid in the skin also has an ultraviolet absorbing effect, and is therefore considered to act protectively against ultraviolet light. Furthermore, the living body also contains enzymes having an active oxygen scavenging action, such as superoxide dismutase (SOD) and catalase, and in vivo antioxidants, such as glutathione.

The present inventor has studied the substance which can be a key, and as a result, it has been found that the substance has a molecular weight of about 6000, which is considered to be an in vivo protective substance acting antioxidatively to ultraviolet rays.
Metallothionein, which is a metal-binding protein, is used as a key substance, and by promoting the production of metallothionein in skin cells, skin damage caused by ultraviolet rays from the sun can be prevented by skin cells themselves. We thought it would be possible to provide an external preparation.

[0010] It has been reported that metallothionein is derived from thionein in vivo by certain heavy metals such as cadmium, zinc, copper, mercury, silver and bismuth. Conventionally, in order to promote the production of metallothionein in vivo, a metallothionein inducer that induces metallothionein from thionein is mainly administered orally, intradermally or intraperitoneally, and can be used as an external preparation. There were few reports on transdermal metallothionein inducers.

This is because cadmium chloride, zinc chloride, and the like, which are conventionally known as metallothionein derivatives, are usually water-soluble and therefore have extremely low transdermal absorbability, and are the only known transdermal metallothionein inducers. Zinc acetate (AJMORGAN, G. LEWIS WEVAN DEN HOVEN
AND PJAKKERBOOM, British Journal of Dermatology
(1993) 129, 563-570) are also not practical in terms of odor for use as transdermal metallothionein inducers.

Therefore, the present inventors examined various compounds to determine whether the induction of metallothionein was caused by transdermal administration. The present inventors have focused on zinc higher fatty acids which may induce metallothionein in vivo by transdermal administration and have no odor problem.

However, it has been found that the higher fatty acid zinc has a problem that it is difficult to transdermally absorb it because of its extremely poor solubility in ordinary water-soluble and oil-soluble solvents.

The problem to be solved by the present invention is to induce metallothionein, which is a key component for protecting a living body from skin injury caused by ultraviolet rays of the sun, in skin cells to promote its production. It is an object of the present invention to find a means for percutaneously absorbing the higher fatty acid zinc obtained, and to provide an external composition for preventing skin injury, which has no problem of odor.

[0015]

The present inventors have made intensive studies on means for percutaneously absorbing the higher fatty acid zinc, and as a result, I.I. O. B. When a polar oil derivative having a value of 0.1 or more is mixed with a higher fatty acid zinc, I.I. O. B. Value is 0.1
It has been found that the higher fatty acid zinc is dissolved in the above polar oil derivative, and as a result, the higher fatty acid zinc can be absorbed percutaneously, and the ability to induce metallothionein in skin cells is dramatically increased.

In addition, sunburn cells, which are necrotic epidermal cells, which can be caused by sunburn, ie, Sunburn cells, are homogenous eosin-philic cytoplasm and vacuoles and enrich for hematoxylin-favorite with hematoxylin-eosin (HE) staining. Cells with isolated nuclei (Hanada, Journal of Nisshinkai 106 (13), 15
59-1561 (1996)), which is considered to be one of the most specific histological changes that occur in the epidermis due to ultraviolet irradiation.

The present inventors examined whether the production of sunburn cells by ultraviolet rays was also suppressed by the induction of metallothionein. As a result, the production of sunburn cells in the epidermis due to ultraviolet irradiation,
I. O. B. By transdermally administering a mixture of a polar oil derivative having a value of 0.1 or more and a higher fatty acid zinc, it is significantly suppressed as compared with the case where only a methoxycinnamic acid derivative having an ultraviolet absorbing effect is transdermally administered. I understood. As described above, since the inhibitory effect of this sunburn cell corresponds to the inducing ability of metallothionein, the effect of metallothionein whose production is promoted in skin cells by percutaneously absorbed higher fatty acid zinc is effected by the antioxidant effect. It is considered to be.

As described above, the present inventor has proposed that I.I. O. B. When a composition containing a polar oil derivative having a value of 0.1 or more and a higher fatty acid zinc is transdermally administered, production of metallothionein in skin cells is promoted, and skin damage due to ultraviolet rays from the sun can be prevented, The inventors have found that the production of sunburn cells in the epidermis due to ultraviolet rays is suppressed and that sunburn can be prevented, and thus the present invention has been completed.

That is, the present inventor described in the present application that I.I.
O. B. A topical composition for preventing skin injuries containing a polar oil derivative having a value of 0.1 or more and a higher fatty acid zinc (hereinafter, referred to as
The composition for external use of the present invention) is provided.

I. O. B. Value (Inorganic Organic Bala
is an index indicating the degree of polarity of the oil component, which is a value indicating the ratio of inorganic to organic [for one carbon atom in the molecule of the oil, the “inorganic value” is defined as 100. , A value calculated based on the inorganic value of another substituent (inorganic group) based on this: [Fujita, "Organic Analysis" (1930) Kania Shoten, same book, "Prediction of organic compounds and organic Conceptual Diagram (Chemical Domain 11-10) "
(1957), Fujita and Akatsuka, "Systematic Organic Qualitative Analysis (Pure Product)", p. 487 (1970), Kazama Shoten,
Koda, "Organic Conceptual Diagram-Basics and Applications", p. 227 (1984)
Year) Sankyo Shuppan, Yaguchi, Emulsion Formulation Design by Organic Conception Diagram, 98 pages (1985) Nippon Emulsion Co., Ltd.
RHEwell, JMHarrison, L. Berg: Ind Eng Chem 36,87
1 (1944)]], and specifically, I.I. O. B. Value = expressed as inorganic value of the oil / organic value of the oil.

I. O. B. If the value is large, it means that the oil phase has high inorganicity and large polarity.

[0022]

Embodiments of the present invention will be described below. A. Components of External Composition of the Present Invention (1) The external composition of the present invention includes: O. B. Value is 0.1
The above polar oil derivative (hereinafter, unless otherwise specified,
"Polar oil derivative").

I. Polar Polar Derivatives O. B. Set the value to 0.
By setting the ratio to 1 or more, it becomes easy to make the higher fatty acid zinc, which is another essential component, compatible, and thereby the percutaneous absorbability of the higher fatty acid zinc can be improved. This I. O. B. When the value is less than 0.1, the polarity becomes weak, and it tends to be difficult to sufficiently dissolve the higher fatty acid zinc.

The polar oil derivative is obtained from I.P. O. B. A derivative of an oil component that satisfies the condition (0.1 or more) regarding the value and that can be generally used as an external composition such as cosmetics;
Specifically, for example, any oil ester derivative, the same carboxyl derivative, the same carboxylate and the like can be used without limitation.

For example, ethyl paramethoxycinnamate, isopropyl paramethoxycinnamate, 2-methoxy paramethoxycinnamate
Ethoxyethyl, 2-ethylhexyl paramethoxycinnamate (also called octyl methoxycinnamate), sodium paramethoxycinnamate, potassium paramethoxycinnamate,
Derivatives of paramethoxycinnamic acid such as glyceryl mono-2-ethylhexamate diparamethoxycinnamate have an ultraviolet shielding effect by themselves, are effective in suppressing the occurrence of sunburn cells, and are preferred polar oil derivatives. On the other hand, di-2-ethylhexyl succinate, pentaerythritol tetra-2-ethylhexanoate,
Glyceryl ethylhexanoate, cetyl octoate, isopropyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, myristyl myristate, decyl oleate, hexyl decyl dimethyl octanoate, cetyl lactate, myristyl lactate, isocetyl stearate, 12 Cholesteryl hydroxystearate, ethylene glycol di-2-ethylhexanoate, neopentyl glycol dicaprate, diisostearyl malate, glyceryl di-2-heptylundecanoate, trimethylolpropane tri-2-ethylhexanoate, triisostearin Trimethylolpropane acid,
Cetyl 2-ethylhexanoate, 2-ethylhexyl palmitate, glyceryl trimyristate, glyceryl tri-2-heptylundecanoate, diisobutyl adipate, 2-octyldodecyl N-lauroyl-L-glutamate, di-2-heptyl adipate Undecyl, ethyl laurate, di-2-ethylhexyl sebacate, 2-hexyldecyl myristate, di-2-hexyldecyl adipate, diisopropyl sebacate, ethyl acetate,
General oil derivatives such as butyl acetate, amyl acetate, and triethyl citrate can also be used.

In the composition for external use of the present invention, the polar oil derivative is appropriately selected and blended depending on the specific use of the composition for external use and the balance with other components, and the like. From the viewpoint of effectiveness, it is particularly preferable to select 2-ethylhexyl paramethoxycinnamate, which is one of the above-mentioned paramethoxycinnamic acid derivatives, and blend it in the composition for external use of the present invention.

The content of the polar oil derivative in the composition for external use of the present invention depends on the specific use, dosage form,
Depending on the balance with other components, etc., is appropriately selected,
There is no particular limitation. Usually, the polar oil component derivative is preferably incorporated in the range of 0.01 to 30.0% by mass relative to the total amount of the composition for external use, preferably 0.1% by mass.
It is particularly preferable that the above compounding be carried out, and it is extremely preferable that the compounding be carried out at 1.0% by mass or more.

The composition for external use of the present invention can contain only one specific polar oil derivative, and if necessary, can contain two or more polar oil derivatives in combination. Of course.

(2) The composition for external use of the present invention contains a higher fatty acid zinc in addition to the above-mentioned polar oil derivative. The higher fatty acid zinc which can be contained in the composition for external use of the present invention is not particularly limited, as long as it does not hinder the inclusion in the composition for external use from the viewpoint of safety and the like. Specifically, fatty acid zinc having 6 or more carbon atoms corresponds to the higher fatty acid zinc of the present invention, and the preferred number of carbon atoms is 8 to 2
0. When the number of carbon atoms is less than 8 or more than 20, the solubility of the higher fatty acid zinc in the polar oil derivative tends to decrease.

Suitable higher fatty acid zinc which can be used in the present invention includes, for example, zinc laurate, zinc myristate,
Examples thereof include zinc palmitate, zinc stearate, zinc undecylenate, zinc caprate, and zinc oleate.

The content of the higher fatty acid zinc in the composition for external use of the present invention is appropriately selected according to the specific use of the composition for external use of the present invention, the dosage form, the balance with other components, and the like. It is not something to be done. Usually, the higher fatty acid zinc is preferably blended in the range of 0.01 to 20.0% by mass relative to the total amount of the composition for external use,
It is particularly preferable to be blended in the range of 10.0% by mass.

If the content of the higher fatty acid zinc is less than 0.01% by mass based on the total amount of the composition for external use, the effect of preventing skin injury, which is expected for the composition for external use of the present invention, may not be sufficiently exhibited. If it exceeds 20.0% by mass, the stability of the base is more likely to be adversely affected.

In the composition for external use of the present invention, only one specific higher fatty acid zinc may be contained, and if necessary, two or more higher fatty acid zinc may be contained in combination. .

As described above, by incorporating the polar oil derivative and the higher fatty acid zinc in combination, the higher fatty acid zinc, which is originally hardly compatible, is compatible, and the percutaneous absorbability of the higher fatty acid zinc is improved. The external use composition of the present invention can be used as a “skin damage prevention external use composition” for protecting a living body in skin cells themselves from skin damage caused by ultraviolet rays from the sun and the like.

That is, when the composition for external use of the present invention is applied to the skin, it promotes the production of metallothionein, which is one of the biological defense mechanisms of the living body itself, in skin cells, and causes skin damage due to exposure to ultraviolet rays. And the production of sunburn cells in the epidermis can be prevented to prevent sunburn. In particular, by selecting a paramethoxycinnamic acid derivative as the polar oil derivative, the polar oil derivative itself can shield the skin from exposure to ultraviolet light, and synergistically suppress skin damage caused by ultraviolet light from the sun. can do. In addition, the composition for external use of the present invention does not have the problem of odor like zinc acetate, and is suitable for transdermal administration in this respect as well.

B. Specific aspects of the composition for external use of the present invention In the composition for external use of the present invention, in addition to the above-described polar oil component derivative and higher fatty acid zinc, components related to medicinal effects, for example, humectants, whitening agents, anti-inflammatory agents, activators, Blood circulation promoter, antiseborrheic,
Plant extract, various vitamins, I. O. B. Ultraviolet absorbers having a value of 0.1 or more that do not correspond to the polar oil derivative, and other components that can be usually blended in the external composition can be blended within a range that does not impair the effects of the present invention.

In the present invention, “external composition” means cosmetics, pharmaceuticals, quasi-drugs, etc. applied to the outer skin, and the dosage form is an aqueous solution type, a solubilizing type, an emulsifying type, a powder type. System, oil-liquid system, gel system, ointment system, aerosol system, water-oil 2
A wide range of dosage forms can be employed, such as a layer system, a water-oil-powder three-layer system, and the like.
For example, for basic cosmetics, face wash, lotion, milky lotion,
It is available in product forms such as creams, gels, essences (cosmetics), pack masks, etc. in the various dosage forms described above. In addition, makeup cosmetics can be widely used in product forms such as foundations. Furthermore, if it is a medicine or a quasi-drug, it can be widely applied in the form of various ointments and the like. The composition for external use of the present invention is not limited in dosage form and product form.

The composition for external use of the present invention may contain, in addition to the above-mentioned essential components and any components relating to the medicinal effect, a known base usually used in the composition for external use, depending on the desired dosage form and product form. Agent components can be blended in a range that does not impair the desired effect of the present invention, and can be produced by a conventional method.

For example, the following components can be appropriately blended: avocado oil, camellia oil, evening primrose oil, turtle oil, macadamia nut oil, corn oil, mink oil, olive oil, rapeseed oil, egg yolk oil, sesame oil, persic Oil, wheat germ oil, sasanqua oil, castor oil, linseed oil,
Safflower oil, cottonseed oil, eno oil, soybean oil, peanut oil, teaseed oil, kaya oil, rice bran oil, sinagiri oil, Japanese kiri oil,
Liquid oils such as jojoba oil, germ oil, triglycerin, glyceryl trioctanoate, glyceryl triisopalmitate;

Cocoa butter, coconut oil, horse fat, hardened coconut oil, palm oil, beef tallow, sheep butter, hardened tallow, palm kernel oil, lard, beef bone fat, mokuro kernel oil, hardened oil, beef leg fat, mokuro Solid oils such as hardened castor oil;

Beeswax, candelilla wax, cotton wax, carnauba wax, bayberry wax, ibota wax, whale wax,
Montan wax, bran wax, lanolin, kapok wax, lanolin acetate, liquid lanolin, sugar cane wax, isopropyl lanolin fatty acid, hexyl laurate, reduced lanolin, jojoba wax, hard lanolin, shellac wax, P
Waxes such as OE lanolin alcohol ether, POE lanolin alcohol acetate, POE cholestanol ether, lanolin fatty acid polyethylene glycol, and POE hydrogenated lanolin alcohol ether; liquid paraffin, ozokerite, squalene, pristane, paraffin, ceresin, squalane, petrolatum, microcristan Hydrocarbon oils such as waxes;

Lauric acid, myristic acid, palmitic acid, stearic acid, behen (behenine) acid, oleic acid, 12-hydroxystearic acid, undecylenic acid,
Higher fatty acids such as tall oil fatty acid, isostearic acid, linoleic acid, linolenic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA);

Lauryl alcohol, cetyl alcohol,
Linear alcohols such as stearyl alcohol, behenyl alcohol, myristyl alcohol, oleyl alcohol, and cetostearyl alcohol, glycerin monostearyl ether (bacyl alcohol), 2-decyltetradecanol, lanolin alcohol, cholesterol, phytosterol, hexyldecanol, and isostearyl alcohol Higher alcohols such as branched-chain alcohols such as octyldodecanol; octyldodecyl myristate, lanolin acetate, isocetyl isostearate, dipentaerythritol fatty acid ester, monoisostearate n-alkylene glycol, castor oil fatty acid methyl,
Synthetic ester oils such as oleyl oleate, 2-heptylundecyl palmitate, and 2-hexyldecyl palmitate (these synthetic ester oils have an IOB value of less than 0.1 or cannot be measured. Thing);

Chain polysiloxanes such as dimethylpolysiloxane, methylphenylpolysiloxane and methylhydrogenpolysiloxane, decamethylpolysiloxane,
Cyclic polysiloxanes such as dodecamethylpolysiloxane and tetramethyltetrahydrogenpolysiloxane, 3
Silicones such as silicone resin and silicone rubber forming a three-dimensional network structure;

Soap base, sodium laurate,
Fatty acid soaps such as sodium palmitate, higher alkyl sulfates such as sodium lauryl sulfate and potassium lauryl sulfate, POE alkyl ether sulfates such as POE lauryl ether triethanolamine, sodium POE lauryl ether sulfate, sodium lauroyl sarcosine, etc. Higher fatty acid amide sulfonates such as N-acyl sarcosine salt, N-myristoyl-N-methyltaurine sodium, coconut oil fatty acid methyltaurine sodium, sodium laurylmethyltaurine, POE sodium oleyl ether phosphate, P
POE alkyl ether phosphate such as sodium OE stearyl ether phosphate, sodium di-2-ethylhexylsulfosuccinate, monosulfo succinate such as monolauroyl monoethanolamide polyoxyethylene sodium sulfosuccinate, sodium lauryl polypropylene glycol sodium sulfosuccinate, linear Alkyl benzene sulfonates such as sodium dodecyl benzene sulfonate, triethanolamine linear dodecyl benzene sulfonate, linear dodecyl benzene sulfonic acid,
N-acylglutamic acid salts such as monosodium N-lauroylglutamate, disodium N-stearoylglutamate and monosodium N-myristoyl-L-glutamate; higher fatty acid ester sulfates such as hydrogenated coconut oil fatty acid sodium glyceryl sulfate; Sulfated oil, POE alkyl ether carboxylic acid, PO
E alkyl allyl ether carboxylate, α-olefin sulfonate, higher fatty acid ester sulfonate, secondary alcohol sulfate, higher fatty acid alkylolamide sulfate, sodium lauroyl monoethanolamide succinate, N-palmitoyl asparagine Anionic surfactants such as acid ditriethanolamine and sodium caseinate;

Stearyltrimethylammonium chloride,
Alkyltrimethylammonium salts such as lauryltrimethylammonium chloride; dialkyldimethylammonium salts such as distearyldimethylammonium chloride; alkylpyridinium salts such as poly (N, N'-dimethyl-3,5-methylenepiperidinium) chloride and cetylpyridinium chloride , Alkyl quaternary ammonium salts, alkyl dimethyl benzyl ammonium salts, alkyl isoquinolinium salts, dialkyl morphonium salts, POE alkylamines, alkylamine salts, polyamine fatty acid derivatives, amyl alcohol fatty acid derivatives, benzalkonium chloride, benzethonium chloride Cationic surfactants such as

Imidazoline compounds such as 2-undecyl-N, N, N- (hydroxyethylcarboxymethyl) -2-imidazoline sodium, 2-cocoyl-2-imitazolinium hydroxide-1-carboxyethyloxy disodium salt, etc. Amphoteric surfactant, 2-heptadecyl-N-
Carboxymethyl-N-hydroxyethylimidazolinium betaine, betaine lauryldimethylaminoacetate,
Amphoteric surfactants such as betaine surfactants such as alkyl betaines, amido betaines and sulfobetaines;

Sorbitan monooleate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesquioleate, sorbitan trioleate, diglycerol sorbitan penta-2-ethylhexanoate, tetra Sorbitan fatty acid esters such as -2-ethylhexanoic acid diglycerol sorbitan, mono-cottonseed oil fatty acid glycerin, glycerin monoerucate, glycerin sesquioleate, glyceryl monostearate, α, α'-glycerol pyroglutamate oleate, monoapple monostearate Glycerin fatty acid esters such as glycerin acid, propylene glycol fatty acid esters such as propylene glycol monostearate, hydrogenated castor oil derivatives, Li serine alkyl ethers, lipophilic nonionic surfactants such as polyoxyethylene-methylpolysiloxane copolymer;

POE sorbitan monooleate, POE
POE sorbitan fatty acid esters such as sorbitan monostearate and POE sorbitan tetraoleate;
OE sorbit monolaurate, POE sorbit monooleate, POE sorbit pentaoleate, PO
POE sorbitol fatty acid esters such as E sorbitol monostearate, POE glycerin monostearate,
POE glycerin fatty acid esters such as POE glycerin monoisostearate and POE glycerin triisostearate; POE fatty acid esters such as POE monooleate, POE distearate and POE dioleate; POE lauryl ether, POE oleyl ether, POE stearyl ether and POE behenyl POE alkyl ethers such as ether, POE2-octyldodecyl ether, POE cholesteryl ether;
POE alkyl phenyl ethers such as E-octyl phenyl ether, POE nonyl phenyl ether, POE dinonyl phenyl ether, Pluronics such as Pluronic, POE POP cetyl ether, POE P
OP2-decyltetradecyl ether, POE / POP
Monobutyl ether, POE / POP hydrogenated lanolin, P
POE / POP alkyl ethers such as OE / POP glycerin ether, tetra-POE / tetra-POP ethylenediamine condensates such as tetronic, POE castor oil, POE-hardened castor oil, POE-hardened castor oil monoisostearate, POE-hardened castor oil POE castor oil or hydrogenated castor oil derivatives such as triisostearate, POE hydrogenated castor oil monopyroglutamic acid monoisostearic acid diester, POE hydrogenated castor oil maleic acid, etc., POE
POE beeswax lanolin derivatives such as sorbit beeswax, alkanolamides such as coconut oil fatty acid diethanolamide, lauric acid monoethanolamide, fatty acid isopropanolamide, POE propylene glycol fatty acid ester, POE alkylamine, POE fatty acid amide, sucrose fatty acid ester, POE Hydrophilic nonionic surfactants such as nonylphenylformaldehyde condensate, alkylethoxydimethylamine oxide, and trioleyl phosphate;

Preservatives such as methyl paraben, ethyl paraben, butyl paraben; edetic acid sodium salt, EDTA
Sequestering agents such as gum arabic, tragacanth gum, galactan, guar gum, carob gum, karaya gum, carrageenan, pectin, agar, quince seed (quince), alge colloid (cassow extract), starch (rice, corn, potato, wheat), glycyrrhizin Natural water-soluble polymers such as plant-based polymers such as acids, microbial polymers such as xanthan gum, dextran, succinoglucan, and pullulan; and animal-based polymers such as collagen, casein, albumin, and gelatin;

Starch polymers such as carboxymethyl starch and methylhydroxypropyl starch such as methylcellulose, nitrocellulose, ethylcellulose, methylhydroxypropylcellulose, hydroxyethylcellulose, sodium cellulose sulfate, hydroxypropylcellulose, sodium carboxymethylcellulose (CMC), crystalline cellulose, Semi-synthetic water-soluble polymers such as cellulose polymers such as cellulose powder, alginic acid polymers such as sodium alginate and propylene glycol alginate;

Vinyl polymers such as polyvinyl alcohol, polyvinyl methyl ether, polyvinyl pyrrolidone, carboxyvinyl polymer (Carbopol), alkyl-modified carboxyvinyl polymer, polyoxyethylene polymers such as polyethylene glycol 2000, 4000 and 6000, and polyoxyethylene polymers Synthetic water-soluble polymers such as oxyethylene polyoxypropylene copolymer-based polymers, acrylic polymers such as sodium polyacrylate, polyethyl acrylate, and polyacrylamide; polyethylene imine; and cationic polymers;

Inorganic water-soluble polymers such as bentonite, aluminum magnesium silicate (Vegum), laponite, hectorite, and silicic anhydride; casein, dextrin, gelatin, sodium pectate, methylcellulose, CMC, hydroxyethylcellulose, hydroxypropylcellulose Thickeners such as, PVA, PVM, PVP, sodium polyacrylate, carboxyvinyl polymer, locust bean gum, guar gum, tamarind gum, dialkyldimethylammonium cellulose sulfate, xanthan gum, aluminum magnesium silicate, bentonite, and hectorite;

Sericite, muscovite, phlogopite,
Synthetic mica, mica, biotite, vermiculite, magnesium carbonate, calcium carbonate, aluminum silicate, barium silicate, calcium silicate, magnesium silicate,
Strontium silicate, metal tungstate, magnesium, silica, zeolite, barium sulfate, calcined calcium sulfate (baked gypsum), calcium phosphate, fluoroapatite, hydroxyapatite, ceramic powder, metal soap (calcium palmitate, aluminum stearate, etc.), Inorganic powder such as boron nitride, polyamide resin powder (nylon powder), polyethylene powder, polymethyl methacrylate powder, polystyrene powder, copolymer resin powder of styrene and acrylic acid, benzoguanamine resin powder, polytetrafluoroethylene powder, cellulose Powder components such as organic powder such as powder;

Inorganic white pigments such as titanium dioxide and zinc oxide, inorganic red pigments such as iron oxide (iron oxide) and iron titanate, inorganic brown pigments such as γ-iron oxide, and inorganic yellow pigments such as yellow iron oxide and loess Pigments, black iron oxide, carbon black, inorganic black pigments such as lower titanium oxide, inorganic violet pigments such as manganese violet and cobalt violet, chromium oxide, chromium hydroxide, inorganic green pigments such as cobalt titanate, Inorganic blue pigments such as ultramarine and navy blue, titanium oxide coated mica, titanium oxide coated bismuth oxychloride, titanium oxide coated talc, colored titanium oxide coated mica, bismuth oxychloride, pearl pigments such as fish scale foil, aluminum powder, copper powder, etc. Metal powder pigments, Red No. 201, Red No. 202, Red 204
No., Red No. 205, Red No. 220, Red No. 226, Red No. 228, Red No. 405, Orange No. 203, Orange No. 204
Organic pigments such as No. 205, Yellow No. 205, Yellow No. 401 and Blue No. 404, Red No. 3, Red No. 104, Red No. 106, Red No. 227, Red No. 230, Red No. 401, Red No. 505
No. Orange No. 205, Yellow No. 4, Yellow No. 5, Yellow No. 202
, Organic pigments such as zirconium, barium or aluminum lake, natural pigments such as chlorophyll, β-carotene, coloring agents such as titanium yellow, carthamine, and safflower red; Water, alcohol etc.

The specific formulation of the composition for external use of the present invention will be described in Examples below.

[0057]

Next, the present invention will be described more specifically with reference to examples. However, the technical scope of the present invention is not limited by the following examples. In addition, about the compounding quantity, unless there is particular notice, it represents the mass% with respect to the object with which the component is compounded.

[Test Examples] In order to evaluate whether or not the composition for external use of the present invention exhibits the expected effects of the present invention, the following tests were conducted.

1. Metallothionein induction test In healthy male volunteers, polar oil derivatives (IOB value of 0.1 or more), higher fatty acid zinc and a mixture thereof were applied to the back, and the metallothionein induction effect was examined.

That is, the following “W / O emulsion composition of a mixture of a polar oil derivative and a higher fatty acid zinc” prepared by a conventional method was applied to the back of a healthy male subject. Fifteen hours after application of the “W / O emulsified composition of a mixture of a methoxycinnamic acid derivative and a higher fatty acid zinc”, the skin on the back was collected (biopsy) to prepare a tissue section specimen, and an anti-horse liver metallothionein antibody (DAK) was prepared.
(Company O) for immunohistochemical staining.

The tissue stained specimen thus prepared was examined for staining with a metallothionein antibody, and classified into four according to the following “criterion”. Table 1 shows the results.

Formulation of W / O Emulsion Composition Mixing Polar Oil Derivative / Higher Fatty Acid Zinc Mixture Glycerin monostearate 0.5% by mass Isostearic acid 3.0% by mass Liquid paraffin 15.0% by mass Polar oil derivative (Table 1) 1.0% by mass Higher fatty acid zinc (described in Table 1) 1.0% by mass Purified water 79.5% by mass

Criteria x: No metallothionein was observed (stained positive cells were less than 30%) Δ: Metallothionein was slightly observed (stained positive cells were less than 30 to 50%) ○: Medium amount of metallothionein was observed (Stained positive cells were less than 50-80%) A: Metallothionein was sufficiently recognized (stained positive cells were 80% or more)

[0064]

[Table 1]

According to the results shown in Table 1, the transdermal administration of the higher fatty acid zinc alone or the polar oil derivative (IOB value of 0.1 or more) alone showed a metallothionein-inducing effect in skin cells. On the other hand, it has been revealed that transdermal administration of a combination of a higher fatty acid zinc and a polar oil component derivative dramatically increases the metallothionein-inducing effect.

This result indicates that the higher fatty acid zinc was transdermally absorbed by dissolving in the polar oil derivative and induced metallothionein in skin cells. 2. Sunburn Cell Production Inhibition Test In healthy male volunteers, a polar oil derivative, higher fatty acid zinc and a mixture thereof were applied to the back, and after application, the effect of inhibiting sunburn cell production was examined.

That is, the following “W / O emulsified composition of a mixture of a polar oil derivative and a higher fatty acid zinc” prepared by a conventional method was applied to the back of a healthy male subject for 3 days. Twenty-four hours after the final application of the “W / O emulsified composition of a mixture of a methoxycinnamic acid derivative and a higher fatty acid zinc”, the back skin surface was wiped off, and 2 × 10 ⁵ J / m ² was applied to the back of the healthy male subject.
Was irradiated (UVB + UVA), and 24 hours later, the skin on the back was collected (biopsy) to prepare a tissue section specimen, and hematoxin-eosin staining was performed.

The number of sunburn cells in the tissue stained specimen thus prepared was counted, and the sunburn cell production inhibitory action was classified into four according to the following criteria based on the number. Table 2 shows the results.

Formulation of W / O Emulsion Composition Mixed with Polar Oil Derivative and Higher Fatty Acid Zinc Glycerin monostearate 0.5% by mass Isostearic acid 3.0% by mass Liquid paraffin 15.0% by mass Polar oil derivative (Table 2) 1.0% by mass Higher fatty acid zinc (described in Table 2) 1.0% by mass Purified water 79.5% by mass

Judgment standard Number of sunburn cells per 1 mm ² (X) ×: Many sunburn cells were observed 2 <X Δ: Medium sunburn cells were observed 1 <X ≦ 2 ○: Slight No sunburn cell was observed 0 <X ≦ 1 ◎: No sunburn cell was observed 0

[0071]

[Table 2]

From the results in Table 2, it was found that transdermal administration of the higher fatty acid zinc alone did not inhibit the production of sunburn cells, whereas transdermal administration of the methoxycinnamic acid derivative alone did not inhibit sunburn due to its ultraviolet absorption effect. While the cell production inhibitory effect was slightly observed, the transdermal administration of a combination of a higher fatty acid zinc and a polar oil derivative (IOB value of 0.1 or more) surprisingly revealed that It was revealed that the cell production inhibitory effect was dramatically increased.

This result corresponds to the fact that the transdermal administration of a combination of a higher fatty acid zinc and a polar oil derivative drastically increases the inducing action of metallothionein, indicating that the higher fatty acid zinc dissolves in the polar oil derivative. Percutaneously absorbed, and induced metallothionein in skin cells, indicating that the production of sunburn cells was suppressed by the antioxidant action of metallothionein.

By transdermal administration of a combination of a higher fatty acid zinc and a polar oil derivative, the production of sunburn cells is suppressed, and as a result, it is clear that skin damage due to ultraviolet rays, particularly sunburn, can be prevented. became.

Hereinafter, general formulations of the composition for external use of the present invention will be shown as examples. When the above-mentioned metallothionein-inducing action test and sunburn cell inhibitory action test were performed on the compositions of these examples, the results of determination of “○” and “◎” were obtained for each of the compositions. In addition, about the smell of each composition,
When the name was sensory evaluated, for any composition,
The determination result was "no odor problem".

Therefore, it has been found that the topical composition of the present invention can sufficiently exhibit the desired effect in any dosage form.

[Example 1] Gel containing powder A gel having the following formulation was prepared by dissolving an aqueous phase with stirring, adding an alcohol phase therein, and stirring. A. Amount of compounding component (% by mass) Aqueous phase Purified water balance Polyethylene glycol 400 5.0 Propylene glycol 5.0 Dipotassium glycyrrhizinate 0.1 Sodium hyaluronate 0.05 Glutathione 2.0 Carboxyvinyl polymer 0.5 Caustic potash 0.2 Sodium hydroxymethoxybenzophenone sulfonate 0 .1 B. Alcohol phase ethanol 10.0 zinc laurate 2.0 octyl methyl cinnamate 10.0 POE (25) octyl dodecyl ether 0.5 2-ethylhexyl paramethoxycinnamate (IOB = 0.35) 0.05 tocopherol acetate 0.1 methyl paraben 0 .1 appropriate amount of fragrance

Example 2 Emulsion An emulsion having the following formulation was prepared by emulsifying with an emulsifier while adding an oily component to an aqueous phase component. A. Amount of compounding component (% by mass) Oil phase Stearic acid 2.0 Cetanol 1.0 Vaseline 2.0 Liquid paraffin 9.0 Cetyl 2-ethylhexanoate 1.0 Jojoba oil 1.0 Squalane 2.0 Pentaerythritol tetra-2-ethylhexanoate 3.0 Methylphenyl polysiloxane 2.0 Zinc laurate 1.0 Methyl octylcinnamate 10.0 Evening primrose oil 0.5 Di-2-methoxycinnamate mono-2-ethylhexanoate 1.5 (IOB = 0.52) POE (10) monooleate 0 1.1 Fine particles of zinc oxide treated with stearic acid (average particle size 0.02 μm) 5.0 Butylparaben 0.2 Perfume Appropriate amount Aqueous phase Propylene glycol 5.0 1,3-butylene glycol 2.0 Arbutin 5.0 Carboxyvinyl polymer 0.2 Triethanolamine 0.2 N-acetylcysteine 3.0 Zinc white 5.0 Purified water balance

Example 3 Cream A cream having the following formulation was prepared by emulsifying with an emulsifier while adding an oily component to an aqueous phase component. A. Amount of compounding component (% by mass) Oil phase Stearic acid 2.0 Stearyl alcohol 7.0 Reduced lanolin 2.0 Olive oil 1.0 Glyceryl tri-2-ethylhexanoate 3.0 Octyldodecanol 5.0 POE (25) cetyl ether 3.0 Glyceryl monostea Rate 2.0 2-ethylhexyl paradimethylaminobenzoate 0.5 (IOB = 0.35) Zinc oxide treated with dextrin palmitate 5.0 (average particle size 0.04 μm) Zinc myristate 2.0 2-Ethylhexyl paramethoxycinnamate 2 0.0 methyl octylcinnamate 10.0 propylparaben 0.3 perfume suitable amount Aqueous phase 1,3-butylene glycol 6.0 dipropylene glycol 3.0 glycerin 4.0 tranexamic acid 2.0 magnesium phosphate-L-ascorbate 0.1 pantothenic acid 0.1 glutathione 2.0 purified water balance

Example 4 Two-Layer Lotion A two-layer lotion having the following formulation was dispersed in the aqueous phase with stirring.
It was prepared by adding an alcohol phase thereto. A. Amount of compounding component (% by mass) Water phase Purified water balance Propylene glycol 4.0 Allantoin 0.2 Salt 0.1 Bentonite 1.0 Talc 0.5 Cellulose powder 0.5 Silica 1.0 Sodium hydroxymethoxybenzophenonesulfonate 0.1 Fine zinc oxide (average Particle size 0.02 μm) 1.0 Alcohol phase Ethanol 15.0 Zinc stearate 2.0 Isopropyl paramethoxycinnamate (IOB = 0.49) 3.0 Ethyl octylcinnamate 8.0 Methyl paraben 0.1 Menthol 0.05 POE (60) glyceryl monoisostearate 0. 5 Tocopherol acetate 0.01 Perfume qs

Example 5 Peel-off type pack A peel-off type pack having the following composition was prepared by dissolving an aqueous phase with stirring and adding an alcohol phase thereto. A. Amount of compounding component (% by mass) Aqueous phase Purified water Residue Polyethylene glycol 1500 5.0 Polyvinyl alcohol 13.0 Placenta extract 0.3 N-acetylcysteine 0.5 Glutathione 5.0 Zinc white 1.0 Fine zinc oxide (average particle size 0.1 μm) 1 2.0 B. Alcohol phase Ethanol 7.0 POE (20) Oleyl alcohol ether 1.0 Zinc undecylenate 0.5 2-Ethylhexyl paramethoxycinnamate (IOB = 0.35) 5.0 Methyl paraben 0.2 Perfume Appropriate amount

Example 6 Sunscreen Cream A sunscreen cream having the following formulation was prepared by emulsifying with an emulsifier while adding an oily component to an aqueous phase component. A. Amount of compounding component (% by mass) Oil phase Zinc laurate 1.0 Zinc undecylenate 0.3 Methyl octylcinnamate 10.0 Sodium paramethoxycinnamate (IOB ≧ 3.11) 1.0 Decamethylcyclopentasiloxane 20.0 Methylpolysiloxane 5.0 POE Glycerol tri Isostearate 1.5 Organically modified viscosity mineral (Benton 38) 0.5 Silicone resin 5.0 Vitamin E acetate 0.05 Methyl paraben 0.5 Alumina treated titanium oxide 5.0 Silicone treated zinc oxide 5.0 (Average particle size 0.02 μm, silicone treatment was carried out by the method described in Japanese Patent Publication No. 1-54381.) Aqueous phase 1,3-butylene glycol 5.0 glycerin 5.0 EDTA.3Na-2H2 O 0.5 glutathione 1.0 purified water balance

[Example 7] Gel containing powder A gel having the following formulation was prepared by dissolving an aqueous phase with stirring, adding an alcohol phase therein, and stirring. A. Amount of compounding component (% by mass) Aqueous phase Purified water balance Polyethylene glycol 400 5.0 Propylene glycol 5.0 Dipotassium glycyrrhizinate 0.1 Sodium hyaluronate 0.05 Glutathione 2.0 Carboxyvinyl polymer 0.5 Caustic potash 0.2 Sodium hydroxymethoxybenzophenone sulfonate 0 .1 B. Alcohol phase ethanol 10.0 zinc laurate 2.0 octyl methyl cinnamate 10.0 POE (25) octyl dodecyl ether 0.5 di-2-ethylhexyl succinate (IOB = 0.32) 0.05 tocopherol acetate 0.1 methyl paraben 0 .1 appropriate amount of fragrance

Example 8 Emulsion An emulsion having the following formulation was prepared by emulsifying with an emulsifier while adding an oily component to an aqueous phase component. A. Amount of compounding component (% by mass) Oil phase Stearic acid 2.0 Cetanol 1.0 Vaseline 2.0 Liquid paraffin 9.0 Cetyl 2-ethylhexanoate 1.0 Jojoba oil 1.0 Squalane 2.0 Pentaerythritol tetra-2-ethylhexanoate 3.0 Methylphenyl polysiloxane 2.0 Zinc laurate 1.0 Pentaerythrit tetra-2-ethylhexanoate 10.0 (IOB = 0.35) Evening primrose oil 0.5 Mono-2-ethylhexamethoxycinnamate Ethyl glyceryl 1.5 POE (10) Monooleate 0.1 Fine particles of zinc oxide treated with stearic acid (average particle size 0.02 μm) 5.0 Butylparaben 0.2 Perfume Appropriate amount Aqueous phase Propylene glycol 5.0 1,3-butylene glycol 2.0 Arbutin 5.0 Carboxyvinyl polymer 0.2 Triethanolamine 0.2 N-acetylcysteine 3.0 Zinc white 5.0 Purified water balance

Example 9 Cream A cream having the following formulation was prepared by emulsifying with an emulsifier while adding an oily component to an aqueous phase component. A. Amount of compounding component (% by mass) Oil phase Stearic acid 2.0 Stearyl alcohol 7.0 Reduced lanolin 2.0 Olive oil 1.0 Glyceryl tri-2-ethylhexanoate (IOB = 0.34) 3.0 Octyldodecanol 5.0 POE (25) cetyl ether 3 2.0 glyceryl monostearate 2.0 2-ethylhexyl paradimethylaminobenzoate 0.5 zinc oxide treated with dextrin palmitate 5.0 (average particle size 0.04 μm) zinc myristate 2.0 2-ethylhexyl paramethoxycinnamate 2 Glyceryl tri-2-ethylhexanoate 10.0 Propylparaben 0.3 Perfume Appropriate amount Aqueous phase 1,3-butylene glycol 6.0 dipropylene glycol 3.0 glycerin 4.0 tranexamic acid 2.0 magnesium phosphate-L-ascorbate 0.1 pantothenic acid 0.1 glutathione 2.0 purified water balance

Example 10 Two-Layer Lotion A two-layer lotion having the following formulation was dispersed in the aqueous phase with stirring.
It was prepared by adding an alcohol phase thereto. A. Amount of compounding component (% by mass) Water phase Purified water balance Propylene glycol 4.0 Allantoin 0.2 Salt 0.1 Bentonite 1.0 Talc 0.5 Cellulose powder 0.5 Silica 1.0 Sodium hydroxymethoxybenzophenonesulfonate 0.1 Fine zinc oxide (average Particle size 0.02 μm) 1.0 Alcohol phase Ethanol 15.0 Zinc stearate 2.0 Isopropyl paramethoxycinnamate (IOB = 0.49) 3.0 Cetyl octanoate 8.0 Methyl paraben 0.1 Menthol 0.05 POE (60) glyceryl monoisostearate 0.5 Tocopherol acetate 0.01 Perfume qs

Example 11 Sunscreen A sunscreen having the following formulation was prepared by emulsifying with an emulsifier while adding an oily component to an aqueous phase component. A. Amount of compounding component (% by mass) Oil phase Decamethylcyclopentasiloxane 28.0 Dimethylpolysiloxane 3.0 2-Ethylhexyl paramethoxycinnamate (IOB = 0.35) 5.0 Polyoxyethylene / methylpolysiloxane copolymer 3.0 Vitamin E acetate 0.02 Myristin Zinc acid 0.5 Organically modified clay mineral 1.0 Spherical polyethylene 3.0 Zinc oxide (hydrophobized product) 18.0 Paraben Suitable amount Fragrance Suitable amount B. Oil phase Dipropylene glycol 5.0 Zinc gluconate 0.1 EDTA · 3Na-2H ₂ O 0.1 Purified water balance

Example 12 Sunscreen Cream A sunscreen cream having the following formulation was prepared by emulsifying with an emulsifier while adding an oily component to an aqueous phase component. A. Amount of compounding component (% by mass) Oil phase Decamethylcyclopentasiloxane 28.0 Dimethylpolysiloxane 3.0 Cetylisooctanoate 2.0 2-Ethylhexyl paramethoxycinnamate (IOB = 0.35) 7.0 Polyoxyethylene / methylpolysiloxane copolymer 0 4-tert-butyl-4'-methoxydibenzoylbutane 0.5 Vitamin E acetate 0.05 Zinc myristate 0.1 Organically modified clay mineral 1.0 Titanium oxide (hydrophobized product) 3.0 Zinc oxide ( Hydrophobized product) 10.0 Paraben qs Flavor qs Water phase Dipropylene glycol 5.0 Zinc gluconate 1.0 EDTA · 3Na-2H ₂ O 0.1 Purified water balance

Example 13 Daytime Cream A daytime cream having the following formulation was prepared by emulsifying with an emulsifier while adding an oily component to an aqueous phase component. A. Amount of compounding component (% by mass) Oil phase Cetanol 2.0 Stearic acid 3.0 2-Ethylhexyl paramethoxycinnamate (IOB = 0.35) 5.0 Zinc myristate 0.05 Jojoba oil 10.0 Self-emulsifying glyceryl monostearate 3.0 Perfume Appropriate amount B . Water phase Dipropylene glycol 7.0 Montmorillonite 1.0 EDTA · 3Na-2H ₂ O 0.07 Sodium hexametaphosphate 0.1 Zinc gluconate 0.5 Triethanolamine 1.0 Purified water balance

Industrial Applicability According to the present invention, there is provided a topical composition having no odor problem, which can promote the production of metallothionein in skin cells and prevent skin damage due to ultraviolet rays from the sun.

──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. ⁷ Identification symbol FI Theme coat ゛ (Reference) A61K 7/00 A61K 7/00 U 31/315 31/315 47/14 47/14 A61P 17/16 A61P 17 / 16 (72) Inventor Eiichiro Yagi 1050 Nippa-cho, Kohoku-ku, Yokohama, Kanagawa Prefecture Inside Shiseido Daiichi Research Center (72) Inventor Haruhi Iwaki 1050 Nippa-cho, Kohoku-ku, Yokohama, Kanagawa Prefecture Shiseido Dai-ichi In one research center (72) Inventor Fumiaki Matsuzaki 1050 Nippa-cho, Kohoku-ku, Yokohama-shi, Kanagawa F-term in Shiseido Daiichi Research Center Co., Ltd. AB172 AB212 AB242 AB332 AB442 AC012 AC022 AC072 AC102 AC122 AC182 AC241 AC242 AC331 AC351 AC421 AC422 AC441 AC442 AC482 AC532 AC5 42 AC622 AC642 AC662 AC682 AC792 AD042 AD092 AD112 AD152 AD162 AD172 AD262 AD332 AD392 AD412 AD512 AD532 AD642 AD662 CC04 CC05 CC07 CC19 DD05 DD23 DD31 DD41 EE17 4C206 AA01 AA02 JB02 KA15 MA02 MA05 MA83 ZA89

Claims (13)

[Claims] 1. I. O. B. An external composition for preventing skin injury, comprising a polar oil derivative having a value of 0.1 or more and a higher fatty acid zinc. 2. I. O. B. The topical composition for preventing skin injury according to claim 1, wherein the polar oil component derivative having a value of 0.1 or more is an oil ester derivative, a carboxyl derivative or a carboxylate thereof. 3. I. O. B. A polar oil derivative having a value of 0.1 or more is a paramethoxycinnamic acid derivative, di-2-ethylhexyl succinate, pentaerythrit tetra-2-ethylhexanoate, glyceryl tri-2-ethylhexanoate, cetyl octanoate, isopropyl myristate, Isopropyl palmitate, butyl stearate, hexyl laurate, myristyl myristate, decyl oleate, hexyl decyl dimethyl octanoate, cetyl lactate, myristyl lactate, isocetyl stearate, cholesteryl 12-hydroxystearate, di-2-ethylhexanoate Ethylene glycol, neopentyl glycol dicaprate, diisostearyl malate, glyceryl di-2-heptylundecanoate, trimethylolpropane tri-2-ethylhexanoate, triisostearin Trimethylolpropane, cetyl 2-ethylhexanoate, 2-ethylhexyl palmitate, glyceryl trimmyristate, glyceryl tri-2-heptylundecanoate, diisobutyl adipate, 2-octyldodecyl N-lauroyl-L-glutamate, diadipate -2-heptylundecyl, ethyl laurate, di-2-ethylhexyl sebacate, 2-hexyldecyl myristate, di-2-hexyldecyl adipate, diisopropyl sebacate, ethyl acetate, butyl acetate, amyl acetate and triethyl citrate The topical composition for preventing skin injury according to claim 1, which is one or more polar oil component derivatives selected from the group consisting of: 4. I. O. B. The topical composition for preventing skin injury according to claim 1, wherein the polar oil derivative having a value of 0.1 or more is a paramethoxycinnamic acid derivative. 5. The topical composition for preventing skin injury according to claim 4, wherein the paramethoxycinnamic acid derivative is 2-ethylhexyl paramethoxycinnamate. 6. The zinc higher fatty acid comprises zinc laurate, zinc myristate, zinc palmitate, zinc stearate,
The topical composition for preventing skin injury according to any one of claims 1 to 5, wherein the composition is one or more zinc higher fatty acids selected from the group consisting of zinc undecylenate, zinc caprate, and zinc oleate. . 7. I. O. B. The content of the polar oil derivative having a value of 0.1 or more is 0.01 to 100% of the total amount of the composition for external use.
The external use composition for skin injury prevention according to any one of claims 1 to 6, which is 30.0% by mass. 8. The skin injury preventing composition according to claim 1, wherein the content of the higher fatty acid zinc is 0.01 to 20.0% by mass based on the total amount of the composition for external use. Topical composition. 9. The composition for external use for preventing skin damage according to claim 1, which prevents skin damage due to exposure to ultraviolet rays. 10. The external composition for preventing skin injury according to claim 1, which promotes the production of metallothionein. 11. The composition for external use for preventing skin injury according to claim 1, which suppresses the production of sunburn cells in skin cells. 12. The externally applied composition for preventing skin injury according to claim 1, which prevents sunburn. 13. The method of claim 1, wherein the higher fatty acid zinc is I.I. O. B. The external composition for preventing skin injury according to any one of claims 1 to 12, which is in a state of being dissolved in a polar oil derivative having a value of 0.1 or more.